Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 12/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090923 | 1.00 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2CFYN | |
| SCHEMBL10531254 | 0.85 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2CCYP19A1 | |
| SCHEMBL9241845 | 0.85 | PNMT (0.59) | PNMTADRA2AADRA2BADRA2CFYN | |
| SCHEMBL24214091 | 0.80 | PNMT (0.59) | PNMTADRA2AADRA2BADRA2CFYN | |
| SCHEMBL8217425 | 0.80 | PNMT (0.59) | PNMTADRA2AADRA2BADRA2CFYN | |
| SCHEMBL9245560 | 0.78 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CPRMT5 | |
| SCHEMBL388968 | 0.78 | CYP19A1 (0.57) | CYP19A1CYP11B2 | |
| SCHEMBL29380284 | 0.77 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL13227654 | 0.77 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6959841 | 0.76 | SLC6A4 (0.50) | PNMTADRA2AADRA2BADRA2CCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803816-B2 | MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1934199-B1 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-1934199-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039462-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078165-A1 | MCH receptor antagonists | BERTHEL STEVEN J | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078165-A1 | MCH receptor antagonists | MCHR1, MCHR2, MC5R | PNMT 233/4885ADRA2A 84/4885ADRA2B 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.